These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22190396)

  • 21. Comparison of the technical and clinical performance of the Elecsys HBsAg II assay with the Architect, AxSym, and Advia Centaur HBsAg screening assays.
    Louisirirotchanakul S; Khupulsup K; Akraekthalin S; Chan KP; Saw S; Aw TC; Cho DH; Shin MG; Lim J
    J Med Virol; 2010 May; 82(5):755-62. PubMed ID: 20336717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana.
    Geretti AM; Patel M; Sarfo FS; Chadwick D; Verheyen J; Fraune M; Garcia A; Phillips RO
    J Clin Microbiol; 2010 Sep; 48(9):3223-30. PubMed ID: 20631103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate.
    Marcellin P; Buti M; Krastev Z; de Man RA; Zeuzem S; Lou L; Gaggar A; Flaherty JF; Massetto B; Lin L; Dinh P; Subramanian GM; McHutchison JG; Flisiak R; Gurel S; Dusheiko GM; Heathcote EJ
    J Hepatol; 2014 Dec; 61(6):1228-37. PubMed ID: 25046847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inter-method variability of hepatitis B surface antigen quantification in a cohort of Egyptian patients with chronic hepatitis B virus.
    Nasser M; Zayed N; Gamal Eldeen H; Abdo M; Kabara Y; Elserafy M
    Arab J Gastroenterol; 2021 Jun; 22(2):151-157. PubMed ID: 34090829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.
    Seto WK; Liu K; Wong DK; Fung J; Huang FY; Hung IF; Lai CL; Yuen MF
    J Hepatol; 2013 Oct; 59(4):709-16. PubMed ID: 23792029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
    Hamers RL; Zaaijer HL; Wallis CL; Siwale M; Ive P; Botes ME; Sigaloff KC; Hoepelman AI; Stevens WS; Rinke de Wit TF;
    J Acquir Immune Defic Syndr; 2013 Oct; 64(2):174-82. PubMed ID: 23892239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.
    Lewin SR; Ribeiro RM; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini SA; Ruxrungtham K; Perelson AS; Dore GJ
    Hepatology; 2009 Apr; 49(4):1113-21. PubMed ID: 19115219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
    Núñez M; Ramos B; Díaz-Pollán B; Camino N; Martín-Carbonero L; Barreiro P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2006 Sep; 22(9):842-8. PubMed ID: 16989608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substantial variation in the hepatitis B surface antigen (HBsAg) in hepatitis B virus (HBV)-positive patients from South Africa: Reliable detection of HBV by the Elecsys HBsAg II assay.
    Gencay M; Vermeulen M; Neofytos D; Westergaard G; Pabinger S; Kriegner A; Seffner A; Gohl P; Huebner K; Nauck M; Kaminski WE
    J Clin Virol; 2018 Apr; 101():38-43. PubMed ID: 29414186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B virus markers in anti-HBc only positive individuals.
    Weber B; Melchior W; Gehrke R; Doerr HW; Berger A; Rabenau H
    J Med Virol; 2001 Jul; 64(3):312-9. PubMed ID: 11424120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B.
    Plaza Z; Aguilera A; Mena A; Vispo E; Sierra-Enguita R; Tomé S; Pedreira J; Rodriguez C; Barreiro P; del Romero J; Soriano V; Poveda E
    AIDS; 2013 Sep; 27(14):2219-24. PubMed ID: 23669158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy.
    Sarkar J; Saha D; Bandyopadhyay B; Saha B; Chakravarty R; Guha SK
    Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of two immunoassays for quantification of hepatitis B surface antigen in Chinese patients with concomitant hepatitis B surface antigen and hepatitis B surface antibodies.
    Liu W; Hu Y; Yang Y; Hu T; Wang X
    Arch Virol; 2015 Jan; 160(1):191-8. PubMed ID: 25323529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intensification of treatment with pegylated interferon alfa in patients coinfected with HIV and HBV genotype H or G being treated with a tenofovir/emtricitabine-containing regimen.
    Mata-Marín JA; Mata-Marín LA; Arroyo-Anduiza CI; Huerta-García G; Sandoval-Ramirez JL; Manjarrez-Tellez B; Gaytán-Martínez JE
    Hepatogastroenterology; 2014; 61(133):1187-91. PubMed ID: 25436280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An improved Abbott ARCHITECT assay for the detection of hepatitis B virus surface antigen (HBsAg).
    Lou SC; Pearce SK; Lukaszewska TX; Taylor RE; Williams GT; Leary TP
    J Clin Virol; 2011 May; 51(1):59-63. PubMed ID: 21367654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term hepatitis B virus surface antigen decay in HIV-1/hepatitis B virus-coinfected adults initiating a tenofovir-containing regimen.
    Tuaillon E; Lozano C; Kuster N; Poinso A; Kania D; Nagot N; Mondain AM; Pageaux GP; Ducos J; Van de Perre P; Reynes J
    J Clin Microbiol; 2012 Sep; 50(9):3096-8. PubMed ID: 22760046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus.
    Boyd A; Gozlan J; Miailhes P; Lascoux-Combe C; Cam MS; Rougier H; Zoulim F; Girard PM; Lacombe K
    AIDS; 2015 Sep; 29(15):1963-73. PubMed ID: 26153669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
    Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
    Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The reliability of HBV core antibody in serological screening for hepatitis B virus.
    Ba Alawi F; Robertson PW; LePage AK; Jayamaha J; Baleriola C; Rawlinson WD
    Pathology; 2013 Aug; 45(5):501-5. PubMed ID: 23842045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of in vivo hepatitis B virus surface antigen mutations-A comparison of four routine screening assays.
    Gencay M; Seffner A; Pabinger S; Gautier J; Gohl P; Weizenegger M; Neofytos D; Batrla R; Woeste A; Kim HS; Westergaard G; Reinsch C; Brill E; Thuy PTT; Hoang BH; Sonderup M; Spearman CW; Brancaccio G; Fasano M; Gaeta GB; Santantonio T; Kaminski WE
    J Viral Hepat; 2018 Oct; 25(10):1132-1138. PubMed ID: 29660206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.